Trials / Unknown
UnknownNCT02220933
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- MedDay Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MD1003 100mg capsule | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-01-01
- Completion
- 2018-01-01
- First posted
- 2014-08-20
- Last updated
- 2017-03-27
Locations
17 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02220933. Inclusion in this directory is not an endorsement.